Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
China BCT Pharmacy Group Inc
CNBIChina BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Retail Pharmacy, and Manufacturing Pharmacy. The Pharmaceutical Distribution segment purchases pharmaceutical products from suppliers and distributes them to hospitals, retail drug stores, other pharmaceutical wholesalers, clinics, medical centers, and individuals. It offers approximately 8,000 pharmaceutical and healthcare products, including branded and generic prescription medicines, over-the counter medicines, and Western and Chinese medicines, as well as personal care products and medical supplies, Chinese herbs, and medical instruments. The Retail Pharmacy segment operates a retail pharmacy network of 196 directly owned stores, primarily in Guangxi province under the Baicaotang name. The retail stores provide professional pharmaceutical services, and supply various medicines, such as prescription medicines, over-the-counter medicines, Chinese herbal medicine, roughly processed Chinese herbal medicine, family planning products, and other pharmaceutical and healthcare products. The Manufacturing Pharmacy segment manufactures and sells generic and clinic drugs, such as traditional anti-inflammatory and antibacterial drugs, cancer treatment drugs, cardio-vascular disease drugs, and hepatitis drugs under the Asio name. Its products comprise Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection. The company was formerly known as China Baicaotang Medicine Limited and changed its name to China BCT Pharmacy Group, Inc. in March 2010. China BCT Pharmacy Group, Inc. was founded in 1956 and is headquartered in Liuzhou, the People's Republic of China. Address: No. 102, Chengzhan Road, Liuzhou, China, 545007
Analytics
Precio Objetivo de WallStreet
4.5 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave CNBI
Análisis de dividendos CNBI
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout CNBI
Valoración de la acción CNBI
Finanzas CNBI
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |